HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMPs Send Smaller Supplement Firms Into Contract Manufacturers’ Arms

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA enforcement of the good manufacturing practices final rule causes some in the supplement industry to question whether small and medium-sized firms can manufacture in-house successfully. Meanwhile, third-party manufacturers are realizing the benefits of a tighter regulatory environment.

You may also be interested in...



Basic GMP Failures Will Prompt Heightened FDA Scrutiny

FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.

People in Brief

Baruch jumps to Schiff from Coca-Cola for chief commercial officer role; Perrigo adds Larson for supply chain security; Revo Biolabs’ Balbert retires again; researcher Bushnell leads NCCAM’s new pain program; USANA hires Smidt as R&D VP; Vega ambassadors head to Olympics.

Herbalife Shakes Off Market Dive After Investor Scare

David Einhorn’s questions during Herbalife’s Q1 earnings call sowed market doubt about the firm, whose stock dropped about 20% May 1. But analysts called the panic behind the sell-off “unwarranted” given the firm’s strong Q1 performance and sound fundamentals.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel